MSInsight has been selected to join 21st, the deeptech accelerator by CentraleSupĂ©lec, one of France’s most prestigious engineering school.
This milestone comes at a decisive moment for MSInsight. Our technology is validated. Our market interest is real. The challenge ahead is clear: accelerating – financially and strategically – to bring MSIcare to cancer patients across Europe.
Why 21st? Because what we need now goes beyond capital. We need the right backing to make informed strategic decisions at a critical inflection point.
At MSInsight, we have spent years building the science, the product, and the clinical evidence. Now is the time to build the company that matches the ambition. We see 21st as the leverage point to transition from early traction to a fully funded, scalable healthtech company. Grateful to the 21st team and the CentraleSupélec ecosystem for their trust. Priscille Raynaud Alex Dunglas Olivier Vaury Romain Marmot
Ready to make the most of it. 🧬
